NCT04878029View on ClinicalTrials.gov

Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

December 11, 2025

Study Completion Date

December 21, 2026

Conditions
Infiltrating Bladder Urothelial Carcinoma with Squamous DifferentiationLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Interventions
DRUG

Cabozantinib S-malate

Given PO

DRUG

Enfortumab Vedotin

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER